• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

    5/14/25 10:45:26 AM ET
    $PRGO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRGO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    PERRIGO CO PLC

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    G97822103

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    G97822103


    1Names of Reporting Persons

    T. Rowe Price Associates, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    MARYLAND
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    11,031,988.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    11,073,026.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    11,073,026.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    8.1 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    PERRIGO CO PLC
    (b)Address of issuer's principal executive offices:

    THE SHARP BUILDING, HOGAN PLACE, DUBLIN, L2, D02TY74
    Item 2. 
    (a)Name of person filing:

    T. Rowe Price Associates, Inc.
    (b)Address or principal business office or, if none, residence:

    1307 Point Street, Baltimore, MD 21231
    (c)Citizenship:

    Maryland
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    G97822103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    11073026
    (b)Percent of class:

    8.1  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    11031988

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    11073026

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    T. Rowe Price Associates, Inc.
     
    Signature:Ellen York
    Name/Title:Vice President
    Date:05/14/2025
    Get the next $PRGO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PRGO

    DatePrice TargetRatingAnalyst
    1/14/2025Buy → Hold
    Argus
    1/6/2025$34.00 → $27.00Overweight → Neutral
    Piper Sandler
    9/24/2024$50.00 → $30.00Hold
    Jefferies
    11/17/2023$37.00Overweight
    Piper Sandler
    3/7/2023$49.00Buy
    Canaccord Genuity
    9/14/2022$46.00Hold → Buy
    Argus
    9/6/2022$48.00 → $54.00Equal Weight → Overweight
    Wells Fargo
    11/11/2021$59.00 → $55.00Outperform
    Raymond James
    More analyst ratings

    $PRGO
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Perrigo Company plc

      SCHEDULE 13G/A - PERRIGO Co plc (0001585364) (Subject)

      6/6/25 12:00:06 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Perrigo Company plc

      144 - PERRIGO Co plc (0001585364) (Subject)

      6/5/25 3:47:21 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Company plc filed SEC Form 8-K: Regulation FD Disclosure

      8-K - PERRIGO Co plc (0001585364) (Filer)

      6/4/25 4:54:22 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Parker Geoffrey M. bought $94,850 worth of Ordinary Shares (3,500 units at $27.10), increasing direct ownership by 17% to 23,762 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/14/25 2:06:42 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Andersen Svend bought $27,900 worth of Ordinary Shares (1,000 units at $27.90), increasing direct ownership by 0.99% to 101,853 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      5/31/24 5:04:45 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ives Alison exercised 1,698 units of Ordinary Shares at a strike of $27.26, covered exercise/tax liability with 1,262 units of Ordinary Shares and bought $67,877 worth of Ordinary Shares (2,490 units at $27.26), increasing direct ownership by 24% to 15,372 units (SEC Form 4)

      4 - PERRIGO Co plc (0001585364) (Issuer)

      3/7/24 9:58:50 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Alford Bradley A

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/17/25 2:22:16 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Parker Geoffrey M.

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/17/25 2:18:53 PM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by EVP & CBDO Ball David

      4 - PERRIGO Co plc (0001585364) (Issuer)

      6/10/25 11:23:22 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PRGO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Perrigo Announces Global Operations and Supply Chain Leadership Transition

      Ron Janish, EVP Global Operations and Supply Chain, to Retire Industry Veteran, Matt Winterman, Appointed EVP Product Supply, Operations Strategy & Transformation Officer DUBLIN, June 4, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading global provider of Consumer Self-Care Products, today announced the appointment of Matt Winterman as Executive Vice President, Product Supply, Operations Strategy and Transformation Officer, effective June 23, 2025. Mr. Winterman succeeds Ron Janish, who will retire from the Company on September 30, 2025, following a distinguished career at Perrigo spanning more than two decades. Both executives will closely work together to ensure a smooth tran

      6/4/25 8:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo to Attend the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference

      DUBLIN, May 23, 2025 /PRNewswire/ -- Perrigo Company plc (NYSE:PRGO), a leading provider of Consumer Self-Care Products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 25th Annual Consumer Growth & E-Commerce Conference, being conducted virtually on Tuesday, June 10 at 9 AM ET. Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts. About Perrigo Perrigo Company plc is a leading pure-play self-care company with over a century of exper

      5/23/25 9:17:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Perrigo Reports First Quarter 2025 Financial Results From Continuing Operations

      Advancing 'Three-S' Plan to Stabilize, Streamline and Strengthen Perrigo, which was Detailed at February 2025 Investor Day Delivered Strong First Quarter 2025 Adjusted EPS Growth and Margin Expansion, Driven by Infant Formula and OTC Brands Widened 2025 Net Sales Target Ranges, Due Primarily to Macroeconomic Uncertainty; Reaffirmed All Other Previously Provided 2025 Financial Targets, Including Adj. EPS Range DUBLIN, May 7, 2025 /PRNewswire/ -- First Quarter 2025 Highlights: Net sales of $1.04 billion declined 3.5%, due primarily to an unfavorable impact of 3.2% from divested

      5/7/25 6:30:00 AM ET
      $PRGO
      Biotechnology: Pharmaceutical Preparations
      Health Care